首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷癌症個人化醫學分子呈像/呈影劑核子醫學

2028 年放射性藥物治療市場預測——按 COVID-19 產品類型,放射性同位素,來源,應用,適應症和最終用戶劃分的影響和全球分析

市場調查報告書

商品編碼

1263754

2028 年放射性藥物治療市場預測——按 COVID-19 產品類型,放射性同位素,來源,應用,適應症和最終用戶劃分的影響和全球分析

Radiopharmaceutical Theranostics Market Forecast to 2028 - Global Analysis By Product Type, Radioisotope, Source, Application, Indication, and End User

出版日期: 2023年03月27日 | 出版商:

The Insight Partners | 英文 185 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

放射性藥物治療診斷市場預計將從 2022 年的 18.1458 億美元增長到 2028 年的 34.4197 億美元，從 2022 年到 2028 年的複合年增長率為 11.3%。癌症發病率上升和在心血管疾病治療中的應用不斷增加是推動市場發展的主要因素。然而，有關批准放射性藥物治療學的監管挑戰阻礙了放射性藥物治療學市場的增長。

放射性藥物在癌症的診斷和治療中具有重要意義。用 123I,124I 或低活性 131I-碘化物進行診斷掃描後，用高活性 131I-碘化物進行治療。類似地，腎上腺素能腫瘤如嗜鉻細胞瘤和神經母細胞瘤可以用 123 I-間碘苯甲基胍成像並用 131 I-間碘苯甲基胍治療。骨閃爍掃描可用於選擇患有晚期,疼痛性前列腺癌骨轉移的患者。發射 BETA 或 ALPHA 粒子的骨閃爍掃描術是對這些患者的有效治療方法。用於診斷和治療神經內分泌腫瘤的生長抑素受體靶向□，分別是 68Ga-DOTATATE 和 177Lu-DOTATATE，是最近建立的治療診斷學之一。

癌症是世界上導致死亡的主要原因之一，據說到 2020 年將有大約 1000 萬人，即近六分之一的人死於癌症。最常見的癌症類型是乳腺癌,肺癌,結腸癌,直腸癌和前列腺癌。根據 2020 年國家癌症登記計劃報告，印度男性癌症患者人數預計將在 2020 年進一步增加至 679,421 人，到 2025 年約為 763,575 人，而女性癌症患者人數預計將在 2020 年增加至 712,758 人，並且估計為 806,218。隨著年齡的增長，我們的免疫系統會減弱，我們更有可能屈服於患癌症的風險。不良的生活習慣,長時間的工作,壓力增加,吸煙,飲酒,使用避孕藥具,未婚和減少母乳喂養都是導致乳腺癌發生的因素。

根據美國癌症協會 2023 年的報告，2023 年將記錄到約 43,720 例甲狀腺癌新病例（12,540 名男性和 31,180 名女性）。據透露，同年將有 2,120 人死於甲狀腺癌（970 名男性和 1,150 名女性）。放射性藥物治療診斷學在癌症治療中具有廣闊的前景。治療診斷學是使用適當放射性藥物的治療和診斷技術的組合。例如，放射性碘在分化型甲狀腺癌的診斷和治療中具有眾所周知的治療應用。幾種放射性藥物可用於乳腺癌應用。這些對包括 43/44Sc/47Sc,64Cu/67Cu,83Sr/89Sr,86Y/90Y,110In/111In,124I/131I,152Tb/161Tb,152Tb/149Tb,68Ga/177Lu 和 90Y/177Lu。 123I/131I 是用於甲狀腺癌治療前後評估的高質量單光子發射計算機斷層掃描 (SPECT)/CT 的治療診斷對的一個著名示例。

惡性神經膠質瘤是一種致命的腫瘤，治療選擇有限。 89Zr 和 177Lu 標記的 Lumi804-ALPHACD11b 是一種很有前途的治療診斷技術，旨在監測和減少膠質瘤中的腫瘤相關髓樣細胞 (TAMC) 並改善免疫治療結果。此外，治療診斷學已被納入用於 PET 成像和靶向放射性藥物治療 (TRT) 的放射性藥物中。用 Lu-177（177Lu-dotatate：Lutathera）或 Ga-68（68Ga-dotatate：NetSpot）放射性標記的 DOTA-octreotate（dotatate）已被 FDA（食品和藥物管理局）批准用於靶向放射性藥物治療（TRT）。）和正電子發射斷層掃描 (PET) 成像。因此，放射性藥物治療診斷方法在各類癌症的診斷和治療中具有前所未有的價值，推動了整個放射性藥物治療診斷市場的增長。

產品類型洞察

放射性藥物治療診斷學市場根據產品類型分為正電子發射斷層掃描 (PET) 示蹤劑,BETA 發射體和 ALPHA 發射體。到 2022 年，正電子發射斷層掃描 (PET) 示蹤劑部分將在放射性藥物治療市場中佔據最大的市場份額，預計在預測期內（2022-2028 年）的複合年增長率最高。 PET 是一種成像技術，可提供有關 PET 放射性藥物生物分佈的定量信息。 PET 成像需要昂貴的設備，例如用於放射性核素生產的迴旋加速器,自動化化學和純化設備以及 PET 相機。 PET 成像用於心髒病學,神經病學和癌症診斷等領域。 PET 可以在其他成像測試揭示疾病之前及早發現疾病的發作。使用正電子發射器（例如鎵 68 和氟 18）的 PET 可以獲得更高的分辨率。由於其高膜滲透性和低氧化還原電位，放射性銅也被開發為一種有前途的示蹤劑，以取代現有的缺氧成像技術。 Ga-PSMA-11 的成功進一步刺激了用於前列腺癌成像的 PSMA 靶向 PET 示蹤劑的開發。此外，治療診斷學 PET 示蹤劑越來越多地用於放射性藥物的開發和應用。作為一種非侵入性系統導航器，治療診斷學 PET 示蹤劑可能有助於選擇最有效的候選藥物,最佳劑量和給藥途徑。因此，高分辨率和活動量化等優勢正在推動 PET 示蹤劑領域的放射性藥物治療市場。

放射性同位素見解

基於放射性同位素，放射性藥物治療診斷學市場包括櫓 (Lu) 177,鎵 68,碘 131,碘 123,鎝 99,釔 90 (Y-90),銅 (Cu) 64,18F ，銅（Cu）67等。到 2022 年，櫓 (Lu) 177 細分市場將在放射性藥物治療市場中佔據最大的市場份額，預計在預測期內（2022-2028 年）的複合年增長率最高，達到 12.3%。 Lutetium-177（177Lu）是核醫學領域的新成員。它有可能在未來幾年內成為使用最廣泛的治療用放射性核素之一。用於癌症治療的 Lu-177 PSMA 療法已用於治療晚期前列腺癌病例。 Lu-177 octreotate 療法用於治療神經內分泌腫瘤 (NETs)，包括頭頸癌和胃腸道腫瘤。櫓療法（lutetium-177-DOTA-oxodotreotide）已被確定為靶向核素療法或□受體放射性核素療法（PRRT）。美國食品和藥物管理局 (FDA) 已批准 177Lu 標記的 DOTA-TATE 用於□受體放射性核素治療 (PRRT)。

來源：洞察力

放射性藥物治療市場根據來源分為迴旋加速器和核反應堆。在 2022 年的放射性藥物治療市場中，迴旋加速器部分將佔據很大的市場份額，預計在預測期內（2022-2028 年）的複合年增長率將更高。迴旋加速器最適合生產富質子放射性同位素，例如氟 18 (18F)。市售的迴旋加速器生產的醫用放射性同位素包括 Carbon-11,Nitrogen-13,Oxygen-15,Fluorine-18 (18F),Copper-64,Gallium-67,Iodine-123 和 thallium-201。根據國際原子能機構 (IAEA) 2023 年報告，迴旋加速器中最常產生的放射性同位素半衰期較短，尤其是氟 18,碳 11,氧 15 和氮 13。用於正電子發射等成像技術斷層掃描（PET）。迴旋加速器佔 PET 所用放射性藥物產量的近 95%。由於放射性核素主要用於研究,診斷和治療各種危及生命的疾病，如癌症,帕金森病,阿爾茨海默病和失眠，因此對迴旋加速器的需求也在增加。此外，PET 和 SPECT 等醫學成像技術依賴迴旋加速器產生的放射性同位素。

應用洞察

根據應用，放射性藥物治療診斷學市場分為靶向治療 (Rx) 和伴隨診斷 (CDx)。在 2022 年的放射性藥物治療市場中，靶向治療 (Rx) 細分市場佔據主要市場份額，預計在預測期內將實現更高的複合年增長率。靶向治療已成為治療不良臨床病症（如癌症）的有前途的策略。例如，“放射性核素”是一種放射療法，它使用細胞靶向分子，如單克隆抗體，注入體內。此外，細胞靶向分子與癌細胞上的特定靶分子結合，殺死靶向癌細胞並最大限度地減少對正常細胞的傷害。靶向療法用於治療前列腺癌和其他癌症。在以下針對神經內分泌胰腺腫瘤中的生長抑素受體的案例中，這一點得到了最好的理解。

68Ga 正在開髮用於生長抑素受體成像，例如 DOTATOC,DOTATATE 和 DOTANOC。生長抑素受體靶向治療可用於新輔助治療，使用 177Lu-DOTATATE (27) 和 90Y-DOTATATE (28) 使不能手術的 pNETs 可切除。 90Y 是一種發射 BETA 的放射性核素，最適合胰腺的大腫瘤。此外，177Lu-DOTATOC和213Bi-DOTATOC表現出較高的生物學效應，在降低胰腺癌細胞活力方面發揮了有效作用。

適應症洞察

根據適應症，放射性藥物治療診斷學市場分為腫瘤學,神經學,心髒病學等。在 2022 年的放射性藥物治療市場中，腫瘤學部分將佔據最大的市場份額，預計在預測期內（2022-2028 年）的複合年增長率最高。治療診斷學涉及將納米粒子注入患者體內並使用光動力療法，為個性化醫療鋪平了道路。這些方法可用於治療食管癌,前列腺癌,乳腺癌,光化性角化病,光化性唇炎,Bowen病,基底細胞上皮瘤和黃斑變性。用於癌症治療的放射性藥物主要是用BETA發射放射性核素標記的。如i-131,Lu-177,釔90(Y-90)放射性核素經常用於此目的。衰變後，釋放的 BETA 粒子失去能量並穿過組織 1-12 毫米，對細胞造成細胞毒性損傷並誘導細胞凋亡。或者，最近，已經探索了 At-211 和 Ac-225 等 ALPHA 發射放射性核素的治療用途。治療診斷學已被臨床醫生和患者成功用於治療前列腺癌。因此，在預測期內，腫瘤學對這些療法和靶向療法的強烈臨床需求繼續推動腫瘤學細分市場。

最終用戶洞察

根據最終用戶，放射性藥物治療市場分為醫院,診斷影像中心,學術和研究機構等。到 2022 年，醫院部分將佔據全球放射性藥物治療市場的最大市場份額。然而，學術和研究機構部分預計在預測期內（2022-2028 年）的複合年增長率最高。該醫院採用技術先進的系統來治療心臟動脈瘤,神經動脈瘤,腫瘤和其他類似疾病。各種疾病患病率的上升和醫院數量的增加促進了醫院放射性藥物治療市場的增長。

內容

第一章介紹

調查範圍
Insight Partners 研究報告指南
市場細分
- 放射性藥物治療診斷學的全球市場 - 按產品類型
- 放射性藥物治療診斷學的世界市場 - 按放射性同位素分類
- 放射性藥物治療診斷學的世界市場 - 按供應商分類
- 全球放射性藥物治療市場 - 按應用分類
- 全球放射性藥物治療市場 - 按適應症分類
- 全球放射性藥物治療市場 - 最終用戶
- 世界放射性藥物治療市場市場 - 按地區

第 2 章放射性藥物治療市場 - 要點

第三章研究方法論

報導
二次調查
關於初步調查

第 4 章放射性藥物治療市場 - 市場格局

害蟲分析
- 北美 PEST 分析
- 歐洲 PEST 分析
- 亞太地區 PEST 分析
- 拉丁美洲 PEST 分析
- 中東和非洲 PEST 分析
專家意見

第 5 章放射性藥物治療市場 - 主要市場動態

市場驅動因素
- 癌症發病率增加
- 在心血管疾病治療中的應用進展
市場製約因素
- 批准放射性藥物治療的監管挑戰
市場機會
- 用於放射性藥物個性化治療的治療診斷數字孿生
未來趨勢
- 核醫學中的放射性藥物治療診斷學
影響分析

第 6 章放射性藥物治療市場 - 全球分析

放射性藥物治療診斷學的全球市場收入和預測/分析
放射性藥物治療學全球市場,區域預測和分析
主要參與者的市場定位
- GE HealthCare Technologies Inc
- Curium

第 7 章全球放射性藥物治療市場 - 按產品類型劃分的收入和到 2028 年的預測

全球放射性藥物治療市場，2021 年和 2028 年按產品類型劃分的銷售額份額 (%)

第 8 章放射性藥物治療診斷學的全球市場分析 - 按放射性同位素

全球放射性藥物治療市場，2021 年和 2028 年按放射性同位素劃分的銷售額份額 (%)

第 9 章放射性藥物治療診斷學的全球市場分析 - 按來源

全球放射性藥物治療市場，2021 年和 2028 年按來源劃分的收入份額 (%)

第 10 章放射性藥物治療診斷學的全球市場分析 - 按應用

2021 年和 2028 年全球放射性藥物治療診斷學市場按應用劃分的收入份額 (%)

第 11 章放射性藥物治療診斷學的全球市場分析 - 按適應症

全球放射性藥物治療市場，2021 年和 2028 年按適應症劃分的銷售份額 (%)

第 12 章放射性藥物治療的全球市場分析 - 按最終用戶

全球放射性藥物治療市場，2021 年和 2028 年最終用戶的銷售份額 (%)

第 13 章放射性藥物治療市場 - 收入和到 2028 年的預測 - 區域分析

北美
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 意大利
- 西班牙
- 其他歐洲
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳大利亞
- 其他亞太地區
中東和非洲
- 沙特阿拉伯
- 南非
- 阿聯酋
- 其他中東和非洲地區
拉丁美洲
- 巴西
- 阿根廷
- 其他南美洲和中美洲

第 14 章 COVID-19 大流行對放射性藥物治療市場的影響

北美
歐洲
亞太地區
中東和非洲
拉丁美洲

第 15 章放射性藥物治療市場 - 行業格局

放射性藥物治療市場的增長戰略
無機增長戰略
有機增長戰略

第十六章公司簡介

Bayer AG
GE HealthCare Technologies Inc
Curium
Lantheus Medical Imaging, Inc.
Telix Pharmaceuticals Ltd.
Cardinal Health Inc
Advanced Accelerator Applications S.A.
Jubilant Radiopharma
Theragnostics
NuView Life Sciences

第十七章附錄

關於 Insight Partners
詞彙表

簡介目錄圖表

Product Code: TIPRE00024328

The radiopharmaceutical theranostics market is expected to reach US$ 3,441.97 million by 2028 from US$ 1,814.58 million in 2022; it is estimated to grow at a CAGR of 11.3% from 2022 to 2028. The rising incidence of cancer and rising application in treatment of cardiovascular disorder are among the key forces bolstering the market. However, regulatory challenges for the approval of radiopharmaceutical theranostics hinder the radiopharmaceutical theranostics market growth.

Radiopharmaceuticals are important in the diagnosis and therapy of cancer; a diagnostic scan with 123I, 124I, or low-activity 131I-iodide is followed by therapy with high-activity 131I-iodide. Similarly, adrenergic tumors such as pheochromocytoma and neuroblastoma can be imaged with 123 I-meta-iodobenzylguanidine and treated with 131 I-metaiodobenzylguanidine. Bone scintigraphy can be used to select patients with painful bone metastases that progressed from prostate cancer. They might benefit from treatment with beta- or alpha-particle-emitting bone-seeking agents, the newest and most successful of which is 223Ra radium chloride. Somatostatin receptor targeting peptides for diagnosing and treating neuroendocrine tumors with agents such as 68Ga-DOTATATE and 177Lu-DOTATATE, respectively, are among the recently established theranostics.

Cancer is one of the leading causes of death worldwide, responsible for almost 10 million deaths in 2020, or almost one in six. The most common types of cancer are breast, lung, colon, rectum, and prostate. According to National Cancer Registry Program Report 2020, in India, male cancer cases were estimated at 679,421 in 2020 and are expected to further increase to about 763,575 in 2025, while female cancer cases were estimated at 712,758 in 2020 and 806,218 in 2025. As people age, they become immunocompromised and often succumb to cancer risks. Poor lifestyles, longer working hours, increasingly stressful lives, smoking, alcohol consumption, contraceptive use, nulliparity, and reduced breastfeeding all contribute to breast cancer incidence.

According to the American Cancer Society's 2023 report, ~43,720 new cases of thyroid cancer (12,540 in men and 31,180 in women) are recorded in 2023. The report also revealed that 2,120 deaths occurred from thyroid cancer (970 in men and 1,150 in women) in the same year. Radiopharmaceutical theranostics have promising potential in cancer therapy. Theranostics is the combination of therapeutic and diagnostic techniques that utilize a suitable radiopharmaceutical agent. For example, radioiodine has a well-known theranostic application in diagnosing and treating differentiated thyroid cancer. Several radiopharmaceutical theranostic pairs are available for breast cancer applications. These pairs include 43/44Sc/47Sc, 64Cu/67Cu, 83Sr/89Sr, 86Y/90Y, 110In/111In, 124I/131I, 152Tb/161Tb, 152Tb/149Tb, 68Ga/177Lu, and 90Y/177Lu. 123I/131I is a well-known example of theranostic pair that is used in high-quality single-photon emission computerized tomography (SPECT)/CT for pre- and post-therapeutic assessment of thyroid cancer.

Malignant gliomas are deadly tumors with the availability of only a few therapeutic options. 89Zr- and 177Lu-labeled Lumi804-αCD11b is a promising theranostic technique intended for monitoring and reducing tumor-associated myeloid cells (TAMCs) in gliomas and improving immunotherapy outcomes. Further, theranostics are incorporated in radiometals for PET imaging and targeted radiopharmaceutical therapy (TRT). DOTA-octreotate (dotatate) radiolabeled with Lu-177 (177Lu-dotatate: Lutathera) or Ga-68 (68Ga-dotatate: NetSpot) are approved by the Food and Drug Administration (FDA) for targeted radiopharmaceutical therapy (TRT) and positron emission tomography (PET) imaging. Thus, a radiopharmaceutical theranostic approach has unprecedented value in diagnosing and treating different types of cancer, which fuels the overall radiopharmaceutical theranostics market growth.

Product Type Insights

Based on product type, the radiopharmaceutical theranostics market is segmented positron emission tomography (PET) tracers, beta emitters, and alpha emitters. In 2022, the positron emission tomography (PET) tracers segment held the largest market share in radiopharmaceutical theranostics market, and it is anticipated to register the highest CAGR during the forecast period (2022-2028). PET is an imaging technique that provides quantitative information on the distribution of PET radiopharmaceuticals in the body. PET imaging requires expensive equipment, which includes a cyclotron for radionuclide production, automated chemistry devices, purification instrumentation, and PET cameras. PET imaging is used in areas such as cardiology, neurology, and cancer diagnosis. PET may detect the early onset of disease before it is evident on other imaging tests. Better resolution can be achieved via PET using positron emitters, such as gallium-68 and fluorine-18. PET tracers featuring radioactive copper have also been developed as a promising alternative for existing hypoxia imaging techniques due to their high membrane permeability and low redox potential. The success of Ga-PSMA-11 further inspired the development of PSMA-targeting PET tracers for imaging prostate cancer. Additionally, theranostics PET tracers are progressively used in radiopharmaceutical drug development and its application. Theranostic PET tracers have the potential to serve as a noninvasive whole-body navigator, which helps select the most effective drug candidates, and determine optimal dosage and administration route. Thus, benefits such as higher resolution, and quantification of activity boost the radiopharmaceutical theranostics market for the PET tracers segment.

Radioisotope Insights

Based on radioisotope, the radiopharmaceutical theranostics market is segmented Lutetium (Lu) 177, Gallium-68, Iodine-131, Iodine-123, Technetium-99, Yttrium-90 (Y-90), Copper (Cu) 64, 18F, Copper (Cu) 67, and others. In 2022, the Lutetium (Lu) 177 segment held the largest market share in radiopharmaceutical theranostics market, and it is anticipated to register the highest CAGR of 12.3% during the forecast period (2022-2028). Lutetium-177 (177Lu) is the latest addition to the field of nuclear medicine. It has potential to become one of the most extensively used therapeutic radionuclides in the coming years. Lu-177 PSMA therapy for cancer theranostic is employed to treat advanced prostate cancer cases. Lu-177 octreotate therapy is used to treat neuroendocrine tumors (NETs), including head and neck cancers and gastrointestinal tumors. Lutetium therapy (lutetium-177-DOTA-oxodotreotide) has been identified as targeted radionuclide therapy or peptide receptor radionuclide therapy (PRRT). The US Food and Drug Administration (FDA) has approved 177Lu-labeled DOTA-TATE for peptide receptor radionuclide therapy (PRRT).

Source Insights

Based on source, the radiopharmaceutical theranostics market is divided into cyclotrons and nuclear reactors. In 2022, the cyclotrons segment held a larger market share in radiopharmaceutical theranostics market and is anticipated to register a higher CAGR during the forecast period (2022-2028). Cyclotrons are best suited for producing proton-rich radioisotopes such as Fluorine-18 (18F). Commercially available cyclotron-produced medical radioisotope involves Carbon-11, Nitrogen-13, Oxygen-15, Fluorine-18 (18F), Copper-64, Gallium-67, Iodine-123, and Thallium-201. According to the International Atomic Energy Agency (IAEA) 2023 report, the most frequent radioisotope produced through cyclotrons are those with short half-lives, particularly fluorine-18, carbon-11, oxygen-15, and nitrogen-13, intended for imaging techniques such as positron emission tomography (PET). Cyclotrons account for almost 95% of the production of radiopharmaceuticals used in PET. Additionally, the demand for cyclotrons is increasing as radionuclides are majorly used in research, diagnosis, and treatment of a range of life-threatening diseases such as cancer, Parkinson's, Alzheimer's, and insomnia. Further, medical imaging techniques such as PET and SPECT depend on cyclotron-produced radioisotopes.

Application Insights

Based on application, the radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and companion diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in radiopharmaceutical theranostics market in 2022, and it is expected to register a higher CAGR during the forecast period. Targeted therapeutics have emerged as a promising strategy for treating harmful clinical conditions, such as cancer. For example, "radionuclide," a type of radiation therapy, uses a cell-targeting molecule such as a monoclonal antibody injected into the body. Further, the cell-targeting molecule binds to a specific target molecule on cancer cells, subsequently killing the targeted cancer cells; the mechanism ensures minimum harm to normal cells. Targeted therapeutics are used for treating prostate cancer and other types of cancers. This is well understood by the following case of targeting somatostatin receptors in neuroendocrine pancreatic tumors.

68Ga has been developed for somatostatin receptor imaging such as DOTATOC, DOTATATE, and DOTANOC. A somatostatin-receptor targeted therapy can be utilized for neoadjuvant therapy that renders inoperable pNET resectable by utilizing 177Lu-DOTATATE (27) and 90Y-DOTATATE (28). 90Y is a beta-emitting radionuclide best suited for bulky pancreatic tumors. Additionally, 177Lu-DOTATOC and 213Bi-DOTATOC have revealed relatively high biological effectiveness, and they are effectively responsible for decreasing the survival of pancreatic adenocarcinoma cells.

Indication Insights

Based on indication, the radiopharmaceutical theranostics market is segmented oncology, neurology, cardiology, and others. The oncology segment held the largest market share in radiopharmaceutical theranostics market in 2022, and it is anticipated to register the highest CAGR during the forecast period (2022-2028). Theranostics methods involve administering nanoparticles into the patient's body and using photodynamic therapy, which paves the way for personalized medicine. These methods can be applied in the treatment of esophageal cancer, prostate cancer, and breast cancer, in the treatment of actinic keratosis, actinic cheilitis, Bowen's disease, basal cell epithelioma, and macular degeneration. Therapeutic radiopharmaceuticals for cancer treatment are predominantly labeled with beta-emitting radionuclides. The radionuclides I-131, Lu-177, and Yttrium-90 (Y-90) are frequently used for this purpose. Upon decay, the emitted beta-particles travel 1-12 mm through tissue while losing energy and causing cytotoxic damage to the cell to induce apoptosis. Alternatively, and more recently, alpha-emitting radionuclides, e.g., At-211 or Ac-225, have been explored for therapeutic applications. Theranostics has been successfully used by clinicians and patients in treating prostate cancer. Thus, the strong clinical need for these therapies and targeted treatments in oncology continue to fuel the market for the oncology segment during the forecast period.

End User Insights

Based on end user, the radiopharmaceutical theranostics market is segmented hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022 of global radiopharmaceutical theranostics market. However, academic and research institutes segment is anticipated to register the highest CAGR during the forecast period (2022-2028). Hospitals employ technologically advanced systems to treat cardiac aneurysms, neurology aneurysms, oncology tumors, and other similar conditions. The rising prevalence of various diseases and an increasing number of hospitals contribute to the growth of the radiopharmaceutical theranostics market for hospitals segment.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the smart hospital beds market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global smart hospital beds market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Global Radiopharmaceutical Theranostics Market - by Product Type
- 1.3.2 Global Radiopharmaceutical Theranostics Market - by Radioisotope
- 1.3.3 Global Radiopharmaceutical Theranostics Market - by Source
- 1.3.4 Global Radiopharmaceutical Theranostics Market - by Application
- 1.3.5 Global Radiopharmaceutical Theranostics Market - by Indication
- 1.3.6 Global Radiopharmaceutical Theranostics Market - by End User
- 1.3.7 Global Radiopharmaceutical Theranostics Market - by Geography

2. Radiopharmaceutical Theranostics Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Radiopharmaceutical Theranostics Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America PEST Analysis
- 4.2.2 Europe PEST Analysis
- 4.2.3 Asia Pacific PEST Analysis
- 4.2.4 South & Central America PEST Analysis
- 4.2.5 Middle East & Africa PEST Analysis
4.3 Expert's Opinion

5. Radiopharmaceutical Theranostics Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Incidence of Cancer
- 5.1.2 Rising Application in Treatment of Cardiovascular Disorders
5.2 Market Restraints
- 5.2.1 Regulatory Challenges for Approval of Radiopharmaceutical Theranostics
5.3 Market Opportunities
- 5.3.1 Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies
5.4 Future Trends
- 5.4.1 Radiopharmaceutical Theranostics in Nuclear Medicine
5.5 Impact Analysis

6. Radiopharmaceutical Theranostics Market - Global Analysis

6.1 Global Radiopharmaceutical Theranostics Market Revenue Forecast and Analysis
6.2 Global Radiopharmaceutical Theranostics Market, by Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
- 6.3.1 GE HealthCare Technologies Inc
- 6.3.2 Curium

7. Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Product Type

7.1 Overview
7.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
- 7.2.1 Positron Emission Tomography (PET) Tracers
  - 7.2.1.1 Overview
  - 7.2.1.2 Positron Emission Tomography (PET) Tracers: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.2.2 Beta Emitters
  - 7.2.2.1 Overview
  - 7.2.2.2 Beta Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.2.3 Alpha Emitters
  - 7.2.3.1 Overview
  - 7.2.3.2 Alpha Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

8. Global Radiopharmaceutical Theranostics Market Analysis - by Radioisotope

8.1 Overview
8.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Radioisotope 2021 & 2028 (%)
- 8.2.1 Technetium-99
  - 8.2.1.1 Overview
  - 8.2.1.2 Technetium-99: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.2 Gallium-68
  - 8.2.2.1 Overview
  - 8.2.2.2 Gallium-68: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.3 Iodine-131
  - 8.2.3.1 Overview
  - 8.2.3.2 Iodine-131: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.4 Iodine-123
  - 8.2.4.1 Overview
  - 8.2.4.2 Iodine-123: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.5 Fluorine-18 (18F)
  - 8.2.5.1 Overview
  - 8.2.5.2 Fluorine-18 (18F): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.6 Yttrium 90 (Y-90)
  - 8.2.6.1 Overview
  - 8.2.6.2 Yttrium 90 (Y-90): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.7 Lutetium (LU) 177
  - 8.2.7.1 Overview
  - 8.2.7.2 Lutetium (LU) 177: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.8 Copper (CU) 67
  - 8.2.8.1 Overview
  - 8.2.8.2 Copper (CU) 67: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.9 Copper (CU) 64
  - 8.2.9.1 Overview
  - 8.2.9.2 Copper (CU) 64: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.10 Others
  - 8.2.10.1 Overview
  - 8.2.10.2 Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

9. Global Radiopharmaceutical Theranostics Market Analysis - by Source

9.1 Overview
9.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Source 2021 & 2028 (%)
- 9.2.1 Nuclear Reactors
  - 9.2.1.1 Overview
  - 9.2.1.2 Nuclear Reactors: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 9.2.2 Cyclotrons
  - 9.2.2.1 Overview
  - 9.2.2.2 Cyclotrons: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

10. Global Radiopharmaceutical Theranostics Market Analysis - by Application

10.1 Overview
10.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Application 2021 & 2028 (%)
- 10.2.1 Targeted Therapeutic (Rx)
  - 10.2.1.1 Overview
  - 10.2.1.2 Targeted Therapeutics (Rx): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 10.2.2 Companion Diagnostic (CDx)
  - 10.2.2.1 Overview
  - 10.2.2.2 Companion Diagnostics (CDx): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

11. Global Radiopharmaceutical Theranostics Market Analysis - by Indication

11.1 Overview
11.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Indication 2021 & 2028 (%)
- 11.2.1 Oncology
  - 11.2.1.1 Overview
  - 11.2.1.2 Oncology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.2 Neurology
  - 11.2.2.1 Overview
  - 11.2.2.2 Neurology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.3 Cardiology
  - 11.2.3.1 Overview
  - 11.2.3.2 Cardiology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.4 Others
  - 11.2.4.1 Overview
  - 11.2.4.2 Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

12. Global Radiopharmaceutical Theranostics Market Analysis - by End User

12.1 Overview
12.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by End User 2021 & 2028 (%)
- 12.2.1 Hospitals
  - 12.2.1.1 Overview
  - 12.2.1.2 Hospitals: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.2 Diagnostic Imaging Centers
  - 12.2.2.1 Overview
  - 12.2.2.2 Diagnostic Imaging Centers: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.3 Academic & Research Institutes
  - 12.2.3.1 Overview
  - 12.2.3.2 Academic & Research Institutes: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.4 Others
  - 12.2.4.1 Overview
  - 12.2.4.2 Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

13. Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - Geographic Analysis

13.1 North America: Radiopharmaceutical Theranostics Market
- 13.1.1 Overview
- 13.1.2 North America: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.1.3 North America: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.1.4 North America: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.1.5 North America: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.1.6 North America: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.1.7 North America: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.1.8 North America: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.1.8.1 United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.1.1 Overview
    - 13.1.8.1.2 United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.1.3 United States Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.8.1.4 United States Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.8.1.5 United States Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.8.1.6 United States Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.8.1.7 United States Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.8.1.8 United States Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.1.8.2 Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.2.1 Overview
    - 13.1.8.2.2 Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.2.3 Canada Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.8.2.4 Canada Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.8.2.5 Canada Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.8.2.6 Canada Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.8.2.7 Canada Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.8.2.8 Canada Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.1.8.3 Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.3.1 Overview
    - 13.1.8.3.2 Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.3.3 Mexico Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.8.3.4 Mexico Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.8.3.5 Mexico Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.8.3.6 Mexico Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.8.3.7 Mexico Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.8.3.8 Mexico Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
13.2 Europe: Radiopharmaceutical Theranostics Market
- 13.2.1 Overview
- 13.2.2 Europe: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.2.3 Europe: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.2.4 Europe: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.2.5 Europe: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.2.6 Europe: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.2.7 Europe: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.2.8 Europe: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.2.9 Europe: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  - 13.2.9.1 Germany: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.1.1 Overview
    - 13.2.9.1.2 Germany Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.1.3 Germany Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.1.4 Germany Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.1.5 Germany Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.1.6 Germany Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.1.7 Germany Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.1.8 Germany Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.2 United Kingdom: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.2.1 Overview
    - 13.2.9.2.2 United Kingdom Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.2.3 United Kingdom Radiopharmaceutical Theranostics Market, by Product type, 2019-2028 (US$ Million)
    - 13.2.9.2.4 United Kingdom Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.2.5 United Kingdom Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.2.6 United Kingdom Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.2.7 United Kingdom Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.2.8 United Kingdom Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.3 France: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.3.1 Overview
    - 13.2.9.3.2 France Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.3.3 France Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.3.4 France Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.3.5 France Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.3.6 France Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.3.7 France Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.3.8 France Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.4 Italy: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.4.1 Overview
    - 13.2.9.4.2 Italy Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.4.3 Italy Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.4.4 Italy Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.4.5 Italy Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.4.6 Italy Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.4.7 Italy Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.4.8 Italy Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.5 Spain: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.5.1 Overview
    - 13.2.9.5.2 Spain Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.5.3 Spain Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.5.4 Spain Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.5.5 Spain Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.5.6 Spain Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.5.7 Spain Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.5.8 Spain Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.6 Rest of Europe: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.6.1 Overview
    - 13.2.9.6.2 Rest of Europe Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.6.3 Rest of Europe Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.6.4 Rest of Europe Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.6.5 Rest of Europe Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.6.6 Rest of Europe Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.6.7 Rest of Europe Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.6.8 Rest of Europe Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
13.3 Asia Pacific: Radiopharmaceutical Theranostics Market
- 13.3.1 Overview
- 13.3.2 Asia Pacific: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.3.3 Asia Pacific: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.3.4 Asia Pacific: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.3.5 Asia Pacific: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.3.6 Asia Pacific: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.3.7 Asia Pacific: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.3.8 Asia Pacific: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.3.9 Asia Pacific: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  - 13.3.9.1 China: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.1.1 Overview
    - 13.3.9.1.2 China: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.1.3 China Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.1.4 China Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.1.5 China Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.1.6 China Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.1.7 China Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.1.8 China Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.2 Japan: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.2.1 Overview
    - 13.3.9.2.2 Japan: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.2.3 Japan Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.2.4 Japan Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.2.5 Japan Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.2.6 Japan Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.2.7 Japan Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.2.8 Japan Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.3 India: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.3.1 Overview
    - 13.3.9.3.2 India: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.3.3 India Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.3.4 India Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.3.5 India Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.3.6 India Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.3.7 India Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.3.8 India Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.4 South Korea: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.4.1 Overview
    - 13.3.9.4.2 South Korea: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.4.3 South Korea Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.4.4 South Korea Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.4.5 South Korea Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.4.6 South Korea Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.4.7 South Korea Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.4.8 South Korea Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.5 Australia: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.5.1 Overview
    - 13.3.9.5.2 Australia: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.5.3 Australia Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.5.4 Australia Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.5.5 Australia Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.5.6 Australia Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.5.7 Australia Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.5.8 Australia Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.6 Rest of Asia Pacific: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.6.1 Overview
    - 13.3.9.6.2 Rest of Asia Pacific: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.6.3 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.6.4 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.6.5 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.6.6 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.6.7 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.6.8 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
13.4 Middle East & Africa Radiopharmaceutical Theranostics Market
- 13.4.1 Overview
- 13.4.2 Middle East & Africa: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.4.3 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.4.4 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.4.5 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.4.6 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.4.7 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.4.8 Middle East & Africa: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.4.9 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  - 13.4.9.1 Saudi Arabia: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.1.1 Overview
    - 13.4.9.1.2 Saudi Arabia Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.1.3 Saudi Arabia Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.4.9.1.4 Saudi Arabia Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.4.9.1.5 Saudi Arabia Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.4.9.1.6 Saudi Arabia Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.4.9.1.7 Saudi Arabia Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.4.9.1.8 Saudi Arabia Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.4.9.2 South Africa: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.2.1 Overview
    - 13.4.9.2.2 South Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.2.3 South Africa Radiopharmaceutical Theranostics Market, by Product type, 2019-2028 (US$ Million)
    - 13.4.9.2.4 South Africa Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.4.9.2.5 South Africa Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.4.9.2.6 South Africa Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.4.9.2.7 South Africa Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.4.9.2.8 South Africa Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.4.9.3 UAE: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.3.1 Overview
    - 13.4.9.3.2 UAE Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.3.3 UAE Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.4.9.3.4 UAE Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.4.9.3.5 UAE Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.4.9.3.6 UAE Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.4.9.3.7 UAE Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.4.9.3.8 UAE Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.4.9.4 Rest of Middle East & Africa: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.4.1 Overview
    - 13.4.9.4.2 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.4.3 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.4.9.4.4 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.4.9.4.5 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.4.9.4.6 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.4.9.4.7 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.4.9.4.8 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
13.5 South & Central America Radiopharmaceutical Theranostics Market
- 13.5.1 Overview
- 13.5.2 South & Central America: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.5.3 South & Central America: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.5.4 South & Central America: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.5.5 South & Central America: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.5.6 South & Central America: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.5.7 South & Central America: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.5.8 South & Central America: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.5.9 South & Central America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  - 13.5.9.1 Brazil: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.1.1 Overview
    - 13.5.9.1.2 Brazil Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.1.3 Brazil Radiopharmaceutical Theranostics Market, by Product type, 2019-2028 (US$ Million)
    - 13.5.9.1.4 Brazil Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.5.9.1.5 Brazil Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.5.9.1.6 Brazil Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.5.9.1.7 Brazil Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.5.9.1.8 Brazil Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.5.9.2 Argentina: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.2.1 Overview
    - 13.5.9.2.2 Argentina Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.2.3 Argentina Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.5.9.2.4 Argentina Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.5.9.2.5 Argentina Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.5.9.2.6 Argentina Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.5.9.2.7 Argentina Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.5.9.2.8 Argentina Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.5.9.3 Rest of South & Central America: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.3.1 Overview
    - 13.5.9.3.2 Rest of South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.3.3 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.5.9.3.4 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.5.9.3.5 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.5.9.3.6 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.5.9.3.7 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.5.9.3.8 Rest of South & Central America Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)

14. Impact Of COVID-19 Pandemic on Radiopharmaceutical Theranostics Market

14.1 North America: Impact Assessment of COVID-19 Pandemic
14.2 Europe: Impact Assessment of COVID-19 Pandemic
14.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
14.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
14.5 South & Central America: Impact Assessment of COVID-19 Pandemic

15. Radiopharmaceutical Theranostics Market - Industry Landscape

15.1 Overview
15.2 Growth Strategies in the Radiopharmaceutical Theranostics Market
15.3 Inorganic Growth Strategies
- 15.3.1 Overview
15.4 Organic Growth Strategies
- 15.4.1 Overview

16. Company Profiles

16.1 Bayer AG
- 16.1.1 Key Facts
- 16.1.2 Business Description
- 16.1.3 Products and Services
- 16.1.4 Financial Overview
- 16.1.5 SWOT Analysis
- 16.1.6 Key Developments
16.2 GE HealthCare Technologies Inc
- 16.2.1 Key Facts
- 16.2.2 Business Description
- 16.2.3 Products and Services
- 16.2.4 Financial Overview
- 16.2.5 SWOT Analysis
- 16.2.6 Key Developments
16.3 Curium
- 16.3.1 Key Facts
- 16.3.2 Business Description
- 16.3.3 Products and Services
- 16.3.4 Financial Overview
- 16.3.5 SWOT Analysis
- 16.3.6 Key Developments
16.4 Lantheus Medical Imaging, Inc.
- 16.4.1 Key Facts
- 16.4.2 Business Description
- 16.4.3 Products and Services
- 16.4.4 Financial Overview
- 16.4.5 SWOT Analysis
- 16.4.6 Key Developments
16.5 Telix Pharmaceuticals Ltd.
- 16.5.1 Key Facts
- 16.5.2 Business Description
- 16.5.3 Products and Services
- 16.5.4 Financial Overview
- 16.5.5 SWOT Analysis
- 16.5.6 Key Developments
16.6 Cardinal Health Inc
- 16.6.1 Key Facts
- 16.6.2 Business Description
- 16.6.3 Products and Services
- 16.6.4 Financial Overview
- 16.6.5 SWOT Analysis
- 16.6.6 Key Developments
16.7 Advanced Accelerator Applications S.A.
- 16.7.1 Key Facts
- 16.7.2 Business Description
- 16.7.3 Products and Services
- 16.7.4 Financial Overview
- 16.7.5 SWOT Analysis
- 16.7.6 Key Developments
16.8 Jubilant Radiopharma
- 16.8.1 Key Facts
- 16.8.2 Business Description
- 16.8.3 Products and Services
- 16.8.4 Financial Overview
- 16.8.5 SWOT Analysis
- 16.8.6 Key Developments
16.9 Theragnostics
- 16.9.1 Key Facts
- 16.9.2 Business Description
- 16.9.3 Products and Services
- 16.9.4 Financial Overview
- 16.9.5 SWOT Analysis
- 16.9.6 Key Developments
16.10 NuView Life Sciences
- 16.10.1 Key Facts
- 16.10.2 Business Description
- 16.10.3 Products and Services
- 16.10.4 Financial Overview
- 16.10.5 SWOT Analysis
- 16.10.6 Key Developments

17. Appendix

17.1 About The Insight Partners
17.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. North America Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 2. North America Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 4. North America Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 5. North America Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 6. North America Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 7. United States Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 8. United States Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 9. United States Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 10. United States Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 11. United States Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 12. United States Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 14. Canada Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 15. Canada Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 16. Canada Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 17. Canada Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 18. Canada Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 19. Mexico Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 20. Mexico Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 21. Mexico Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 22. Mexico Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 23. Mexico Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 24. Mexico Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 25. Europe Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 26. Europe Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 27. Europe Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 28. Europe Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 29. Europe Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 30. Europe Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 31. Germany Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 32. Germany Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 33. Germany Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 34. Germany Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 35. Germany Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 36. Germany Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 37. United Kingdom Radiopharmaceutical Theranostics Market, by Product type - Revenue and Forecast to 2028 (US$ Million)
Table 38. United Kingdom Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 39. United Kingdom Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 40. United Kingdom Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 41. United Kingdom Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 42. United Kingdom Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 43. France Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 44. France Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 45. France Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 46. France Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 47. France Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 48. France Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 49. Italy Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 50. Italy Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 51. Italy Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 52. Italy Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 53. Italy Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 54. Italy Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 55. Spain Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 56. Spain Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 57. Spain Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 58. Spain Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 59. Spain Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 60. Spain Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 61. Rest of Europe Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 62. Rest of Europe Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 63. Rest of Europe Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 64. Rest of Europe Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 65. Rest of Europe Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 66. Rest of Europe Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 67. Asia Pacific Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 68. Asia Pacific Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 69. Asia Pacific Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 70. Asia Pacific Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 71. Asia Pacific Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 72. Asia Pacific Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 73. China Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 74. China Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 75. China Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 76. China Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 77. China Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 78. China Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 79. Japan Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 80. Japan Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 81. Japan Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 82. Japan Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 83. Japan Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 84. Japan Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 85. India Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 86. India Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 87. India Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 88. India Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 89. India Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 90. India Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 91. South Korea Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 92. South Korea Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 93. South Korea Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 94. South Korea Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 95. South Korea Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 96. South Korea Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 97. Australia Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 98. Australia Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 99. Australia Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 100. Australia Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 101. Australia Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 102. Australia Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 103. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 104. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 105. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 106. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 107. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 108. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 109. Middle East & Africa Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 110. Middle East & Africa Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 111. Middle East & Africa Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 112. Middle East & Africa Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 113. Middle East & Africa Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 114. Middle East & Africa Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 115. Saudi Arabia Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 116. Saudi Arabia Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 117. Saudi Arabia Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 118. Saudi Arabia Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 119. Saudi Arabia Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 120. Saudi Arabia Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 121. South Africa Radiopharmaceutical Theranostics Market, by Product type - Revenue and Forecast to 2028 (US$ Million)
Table 122. South Africa Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 123. South Africa Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 124. South Africa Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 125. South Africa Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 126. South Africa Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 127. UAE Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 128. UAE Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 129. UAE Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 130. UAE Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 131. UAE Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 132. UAE Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 133. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 134. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 135. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 136. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 137. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 138. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 139. South & Central America Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 140. South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 141. South & Central America Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 142. South & Central America Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 143. South & Central America Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 144. South & Central America Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 145. Brazil Radiopharmaceutical Theranostics Market, by Product type - Revenue and Forecast to 2028 (US$ Million)
Table 146. Brazil Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 147. Brazil Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 148. Brazil Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 149. Brazil Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 150. Brazil Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 151. Argentina Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 152. Argentina Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 153. Argentina Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 154. Argentina Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 155. Argentina Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 156. Argentina Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 157. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 158. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 159. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 160. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 161. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 162. Rest of South & Central America Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 163. Recent Inorganic Growth Strategies in the Radiopharmaceutical Theranostics Market
Table 164. Recent Organic Growth Strategies in the Radiopharmaceutical Theranostics Market
Table 165. Glossary of Terms

List Of Figures

Figure 1. Radiopharmaceutical Theranostics Market Segmentation
Figure 2. Radiopharmaceutical Theranostics Market, by Region
Figure 3. Global Radiopharmaceutical Theranostics Market Overview
Figure 4. Positron Emission Tomography (PET) Tracers Segment Held Largest Share of Product Type Segment in Radiopharmaceutical Theranostics Market
Figure 5. Asia Pacific Expected to Show Remarkable Growth During Forecast Period
Figure 6. Radiopharmaceutical Theranostics Market, by Geography (US$ Million)
Figure 7. Global Radiopharmaceutical Theranostics Market - Leading Country Markets (US$ Million)
Figure 8. Global Radiopharmaceutical Theranostics Market - Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. South & Central America: PEST Analysis
Figure 13. Middle East & Africa: PEST Analysis
Figure 14. Experts' Opinion
Figure 15. Radiopharmaceutical Theranostics Market: Impact Analysis of Drivers and Restraints
Figure 16. Global Radiopharmaceutical Theranostics Market - Revenue Forecast and Analysis - 2020-2028
Figure 17. Global Radiopharmaceutical Theranostics Market, by Geography - Forecast and Analysis (2021-2028)
Figure 18. Market Positioning of Key Players in Radiopharmaceutical Theranostics Market
Figure 19. Global Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
Figure 20. Positron Emission Tomography (PET) Tracers: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 21. Beta Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 22. Alpha Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 23. Global Radiopharmaceutical Theranostics Market, by Radioisotope, 2021 & 2028 (%)
Figure 24. Technetium-99: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 25. Gallium-68: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 26. Iodine-131: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 27. Iodine-123: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 28. Fluorine-18 (18F): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 29. Yttrium 90 (Y-90): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 30. Lutetium (LU) 177: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 31. Copper (CU) 67: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 32. Copper (CU) 64: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. Global Radiopharmaceutical Theranostics Market, by Source, 2021 & 2028 (%)
Figure 35. Nuclear Reactors: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 36. Cyclotrons: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 37. Global Radiopharmaceutical Theranostics Market, by Application, 2021 & 2028 (%)
Figure 38. Targeted Therapeutics (Rx): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 39. Companion Diagnostics (CDx): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 40. Global Radiopharmaceutical Theranostics Market, by Indication, 2021 & 2028 (%)
Figure 41. Oncology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 42. Neurology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 43. Cardiology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 44. Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 45. Global Radiopharmaceutical Theranostics Market, by End User, 2021 & 2028 (%)
Figure 46. Hospitals: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 47. Diagnostic Imaging Centers: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 48. Academic & Research Institutes: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 49. Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 50. North America: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 51. North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 52. North America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
Figure 53. United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 54. Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 55. Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 56. Europe: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 57. Europe Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 58. Europe: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
Figure 59. Germany Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 60. United Kingdom Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 61. France Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 62. Italy Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 63. Spain Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 64. Rest of Europe Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 65. Asia Pacific: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 66. Asia Pacific Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 67. China: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 68. Japan: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 69. India: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 70. South Korea: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 71. Australia: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 72. Rest of Asia Pacific: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 73. Middle East & Africa: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 74. Middle East & Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 75. Saudi Arabia Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 76. South Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 77. UAE Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 78. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 79. South & Central America: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 80. South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 81. South & Central America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
Figure 82. Brazil Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 83. Argentina Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 84. Rest of South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 85. Impact of COVID-19 Pandemic on North American Country Markets
Figure 86. Impact of COVID-19 Pandemic in European Country Markets
Figure 87. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 88. Impact of COVID-19 Pandemic in Middle East & Africa Country Markets
Figure 89. Impact of COVID-19 Pandemic on South & Central American Country Markets
Figure 90. Growth Strategies in the Radiopharmaceutical Theranostics Market